SCHEMBL6466418

SCHEMBL6466418

Cc1c(-c2ccc(C#N)cc2)c(C#N)c(C(C)C)n1Cc1cccnc1

nearest known ligand 0.80

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AR P10275 8/20 0.80
CYP11B2 P19099 2/20 0.41
GNRHR P30968 1/20 0.37
CYP19A1 P11511 1/20 0.36
CYP3A4 P08684 1/20 0.36
CASP1 P29466 2/20 0.36
CASP7 P55210 2/20 0.36
HSD17B10 Q99714 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
CYP11B1 P15538 1/20 0.35
PDE9A O76083 1/20 0.35
PDE1C Q14123 1/20 0.35
DYRK1A Q13627 1/20 0.35
USP1 O94782 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6465272 0.89 AR (1.00) ARCYP11B2CYP19A1CYP3A4CASP1
SCHEMBL6464186 0.84 AR (0.81) ARCYP11B2CYP3A4HSD17B10ALDH1A1
SCHEMBL6464828 0.81 AR (0.77) ARCYP11B2GNRHRCYP19A1CYP3A4
SCHEMBL5251476 0.80 AR (0.60) AR
SCHEMBL6464840 0.80 AR (0.78) ARCYP11B2CYP11B1PDE9APDE1C
SCHEMBL6465363 0.79 AR (0.76) ARCYP11B2CYP3A4CASP1CASP7
SCHEMBL6468892 0.77 AR (0.77) ARCYP11B2CYP19A1CYP3A4HSD17B10
SCHEMBL6469609 0.77 AR (0.70) ARCYP11B2CYP19A1CYP3A4HSD17B10
SCHEMBL6469333 0.77 AR (0.66) ARALDH1A1
SCHEMBL6889299 0.77 AR (0.72) ARCYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050101657-A1 Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative TAKEDA CHEMICAL INDUSTRIES LTD. (JP) 2005-05-12 US disclosed
EP-1466902-A1 ANDROGEN RECEPTOR ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2004-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101657-A1 Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative SHBG, PRLHR, FSHR AR 6/4885CYP11B2 151/4885GNRHR 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.